Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Multidrug Resistance Seen in 6.2% of Tuberculosis Patients
May 7, 2001
- Nikken Chemical to Codevelop Sustained-release hGH with InfiMed of the US
May 7, 2001
- Solidifing Business Base by Increasing Productivity: Mochida President
May 7, 2001
- Large Study on Antihypertensives Planned: CASE-J
May 7, 2001
- Kyorin Sets Up Its First Overseas Business Base in US
May 7, 2001
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
May 7, 2001
- FPMAJ Issues GL for Paper, Plastic Discrimination Labeling
May 7, 2001
- Key Points of New Criteria for Drug-or-Food Judgment
May 7, 2001
- Future of Japanese Firms Is Not Easy: Nihon Univ. Seminar
May 7, 2001
- METI to Promote Industry, Government, Academia Alliance through BECON: Mr Okakura
May 7, 2001
- BUSINESS NEWS IN BRIEF -1-
May 7, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF -2-
May 7, 2001
- BUSINESS NEWS IN BRIEF -2-
May 7, 2001
- Takeda Discovers Respiratory Disease-related Genes
May 7, 2001
- Only 2 out of 20 Keidanren Deregulation Proposals Implemented
May 7, 2001
- Short-acting Insulin Analog Treatment Effective in Type 2 Diabetes: JDA/Lilly Seminar
May 7, 2001
- 27 GEs Delisted 1 Year after Application of GE Rule
May 7, 2001
- Many Psychiatrists Dissatisfied with Drugs to Treat Schizophrenia
May 7, 2001
- BUSINESS NEWS IN BRIEF -2-
April 23, 2001
- Ain Pharmaciez, Nice Drug to Jointly Operate Large Dispensing Pharmacies in Tokai
April 23, 2001
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…